advertisement
Abstract #98807 Published in IGR 22-4
CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Wu WH; Tsai YT; Huang IW; Huang IW; Cheng CH; Hsu CW; Cui X; Ryu J; Quinn PMJ; Quinn PMJ; Quinn PMJ; Caruso SM; Caruso SM; Lin CS; Tsang SHMolecular Therapy 2022; 30: 1407-1420
Mutations in rhodopsin (RHO) are the most common causes of autosomal dominant retinitis pigmentosa (adRP), accounting for 20% to 30% of all cases worldwide. However, the high degree of genetic heterogeneity makes development of effective therapies cumbersome. To provide a universal solution to RHO-related adRP, we devised a CRISPR-based, mutation-independent gene ablation and replacement (AR) compound therapy carried by a dual AAV2/8 system. Moreover, we developed a novel hRHO/hRHO humanized mouse model to assess the AR treatment in vivo. RESULTS: show that this humanized RHO mouse model exhibits progressive rod-cone degeneration that phenocopies hRHO/hRHO patients. In vivo transduction of AR AAV8 dual vectors remarkably ablates endogenous RHO expression and overexpresses exogenous WT hRHO. Furthermore, the administration of AR during adulthood significantly hampers photoreceptor degeneration both histologically and functionally for at least 6 months compared with sole gene replacement or surgical trauma control. This study demonstrates the effectiveness of AR treatment of adRP in the human genomic context while revealing the feasibility of its application for other autosomal dominant disorders.
Jonas Children's Vision Care and the Bernard & Shirlee Brown Glaucoma Laboratory, Department of Ophthalmology, Columbia Stem Cell Initiative, Columbia University, New York, NY 10032, USA; Edward S. Harkness Eye Institute, New York-Presbyterian Hospital/Columbia University Medical Center, New York, NY 10032, USA.
Full article